Misregulation of kinase activity is a primary cause of many types of cancer; therefore, protein kinases are a major target for oncology drug discovery.2 GTs catalyse the transfer of a sugar from a donor (e.g. UDP-sugar) to a variety of acceptors (e.g. oligosaccharides, proteins, lipids)3 and have been identified as promising drug targets to treat tuberculosis and metabolic disorders; yet only two GT inhibitors are in clinical use.4 Progress in GT inhibitor development is limited by the lack of robust, label-free tools for conducting high-throughput screening (HTS) assays. Here, WEE1 is linked to cancer.